Acesso livre
Acesso livre

[Preprint] Estudo RECOVERY descobre que a combinação de anticorpo monoclonal Regeneron reduz as mortes de pacientes hospitalizados com COVID que não desenvolveram sua própria resposta imunológica.

17 Jun, 2021 | 11:04h

Comunicado de imprensa: RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

Estudo original (preprint): Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv

Comentários: Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients – Science E Antibody combo cuts COVID deaths by 20% in very ill seronegative patients – CIDRAP E Regeneron antibody saves lives in some hospitalized Covid patients, study finds – STAT E Expert reaction to press release from the RECOVERY trial reporting that Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response – Science Media Centre

 

Comentário no Twitter

 


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.